WORK Medical Technology Group LTD Announces US$1 Million Equity Investment in Neologics Bioscience
WORK Medical (NASDAQ: WOK) agreed to invest US$1 million in Neologics Bioscience to acquire a 10% equity interest via newly issued shares, on a post-investment basis. The transaction raises Neologics's total capital reserve to US$10 million and leaves the existing shareholder with a 90% stake.
WORK Medical gains governance rights tied to its 10% holding, a right of first refusal on future equity offers, and expects Neologics to complete registration and issue an equity certificate within 20 working days. Proceeds will support operations, R&D, market expansion, and hiring.
WORK Medical (NASDAQ: WOK) ha concordato di investire US$1 milione in Neologics Bioscience per acquisire una quota azionaria del 10% tramite nuove azioni emesse, su base post-investimento. La transazione porta la riserva di capitale totale di Neologics a US$10 milioni e lascia al socio esistente una partecipazione del 90%.
WORK Medical ottiene diritti di governance legati alla sua quota del 10%, un diritto di prelazione sulle future offerte di capitale, e si aspetta che Neologics completi la registrazione ed emetta un certificato azionario entro 20 giorni lavorativi. I proventi sosterranno le operazioni, la ricerca e sviluppo, l'espansione nel mercato e le assunzioni.
WORK Medical (NASDAQ: WOK) acordó invertir US$1 millón en Neologics Bioscience para adquirir una participación accionaria del 10% mediante nuevas acciones emitidas, sobre una base post-inversión. La transacción eleva la reserva de capital total de Neologics a US$10 millones y deja al accionista existente con una participación del 90%.
WORK Medical obtiene derechos de gobernanza ligados a su tenencia del 10%, un derecho de tanteo sobre futuras ofertas de acciones y espera que Neologics complete el registro y emita un certificado de acciones dentro de 20 días hábiles. Los ingresos se destinarán a operaciones, I+D, expansión de mercado y contratación.
WORK Medical (NASDAQ: WOK)가 Neologics Bioscience에 미화 100만 달러를 투자해 신규 발행 주식을 통한 10% 지분을 취득하기로 합의했습니다. 이는 투자 후 기준입니다. 거래로 Neologics의 총 자본 준비금은 미화 1000만 달러로 증가하고 기존 주주는 90%의 지분을 보유하게 됩니다.
WORK Medical은 10% 보유 지분과 연계된 지배권, 향후 지분 제안에 대한 선매권을 얻고, Neologics가 등록을 마치고 20 영업일 이내에 주권 증서를 발행할 것으로 기대합니다. 자금은 운영, R&D, 시장 확장 및 채용에 사용될 예정입니다.
WORK Medical (NASDAQ: WOK) a accepté d'investir 1 million de dollars US dans Neologics Bioscience pour acquérir une participation de 10 % du capital via des actions nouvellement émise, sur une base post-investissement. La transaction porte la réserve de capital totale de Neologics à 10 millions de dollars US et laisse à l'actionnaire existant une participation de 90 %.
WORK Medical obtient des droits de gouvernance liés à sa participation de 10 %, un droit de premier refus sur les futures offres d'actions, et s'attend à ce que Neologics termine l'enregistrement et émette un certificat d'actions dans 20 jours ouvrables. Le produit de la transaction sera utilisé pour les opérations, la R&D, l'expansion du marché et le recrutement.
WORK Medical (NASDAQ: WOK) hat sich bereit erklärt, 1 Million US-Dollar in Neologics Bioscience zu investieren, um eine 10%-Beteiligung mittels neu ausgegebener Aktien zu erwerben, basierend auf dem Post-Investment-Verfahren. Die Transaktion erhöht Neologics' gesamtes Kapitalreservenbestand auf 10 Millionen US-Dollar und lässt den bestehenden Aktionär mit einem Anteil von 90% zurück.
WORK Medical erhält Governance-Rechte, die an seine 10%-Beteiligung gebunden sind, ein Vorrecht auf zukünftige Aktienangebote und erwartet, dass Neologics die Registrierung abschließt und innerhalb von 20 Werktagen eine Aktienurkunde ausgibt. Die Erlöse dienen Betriebs-, F&E-, Marktexpansion und Personalbeschaffung.
WORK Medical (ناسداك: WOK) وافقت على استثمار مليون دولار أمريكي في Neologics Bioscience لاقتناء حقوق ملكية بنسبة 10% من خلال أسهم جديدة مُصدرة، بناءً على أساس ما بعد الاستثمار. الصفقة ترفع الاحتياطي الرأسمالي الكلي لـ Neologics إلى عشرة ملايين دولار أمريكي وتترك للمساهم الحالي حصة نسبتها 90%.
تكتسب WORK Medical حقوق حوكمة مرتبطة بحيازتها البالغة 10%، و< b>حق الرفض الأول في عروض الأسهم المستقبلية، وتتوقع أن تستكمل Neologics التسجيل وتصدر شهادة الأسهم خلال 20 يوم عمل. ستُستخدم العائدات في العمليات و R&D وتوسيع السوق والتوظيف.
WORK Medical (NASDAQ: WOK) 同意投资 100万美元，通过新发行的股票在 Neologics Bioscience 获得 10% 的股权，以投资后的基准计算。此交易使 Neologics 的总资本准备金增加至 1000万美元，现有股东持有 90% 的股权。
WORK Medical 获得与其 10% 持股相关的治理权、未来增发时的 优先购买权，并预计 Neologics 将在 20 个工作日 内完成注册并发行股权证书。募集资金将用于运营、研发、市场扩张和招聘。
- US$1 million investment for a 10% equity stake
- Post-money capital reserve increased to US$10 million
- Includes right of first refusal on future equity
- Governance rights to nominate board members
- 10% stake is a minority holding, limiting control
- No revenue or ROI targets disclosed for the investment
Insights
WORK Medical buys a 10% stake in Neologics for
WORK Medical subscribes for newly issued shares to acquire a
This is a strategic minority investment that gives WORK Medical exposure to AI‑driven medical R&D while keeping control with the existing shareholder. Key dependencies include timely completion of registration and issuance within
Hangzhou, China, Oct. 21, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that it has entered into an investment agreement (the “Investment Agreement”) with Neologics Bioscience Inc. (“Neologics”), a Delaware-based medical technology company specializing in research and development of medical technologies, with a focus on the integration of artificial intelligence and medicine (the “R&D”), to invest US
The investment proceeds are expected to be primarily used to support Neologics’s operations, R&D, market expansion, talent acquisition, and other legitimate business purposes. Neologics has agreed to complete all necessary corporate registration, shareholder filings, and the issuance of an equity certificate within 20 working days following the execution of the Investment Agreement.
Mr. Shuang Wu, chief executive officer and chairman of the board of directors of WORK Medical, commented: “We are excited to partner with Neologics, which marks a key step in advancing our strategic focus on innovation and global collaboration in the medical technology field. By combining Neologics’s R&D capabilities with WORK Medical’s industry experience and operational strengths, we expect this partnership to unlock synergies and growth potential. Together, we aim to foster technological innovation, drive mutual advancement, and deliver sustainable value to both companies and our stakeholders.”
About WORK Medical Technology Group LTD
WORK Medical Technology Group LTD, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, is a supplier of medical devices that develops and manufactures Class I and II medical devices and sells Class I and II disposable medical devices through operating subsidiaries in China. The Company has a diverse product portfolio comprising 21 products, including customized and multifunctional masks and other medical consumables. All the products have been sold in 34 provincial-level administrative regions in China, with 15 of them sold in more than 30 countries worldwide. The Company has received a number of quality-related manufacturing designations and has registered 17 products with the U.S. Food and Drug Administration allowing their products to enter the U.S. market. For more information, please visit the Company’s website: https://www.workmedtech.com/corporate.
Forward-Looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Any forward-looking statements in this press release are based on the Company’s current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results set forth in the Company’s annual report on Form 20-F and other documents filed by the Company with the U.S. Securities and Exchange Commission. The Company explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
For more information, please contact:
WORK Medical Technology Group LTD
Investor Relations Department
Email: ir@workmedtech.com
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
FAQ
What did WORK Medical (WOK) announce on October 21, 2025?
How much ownership will WORK Medical hold in Neologics after the deal?
What rights does WORK Medical gain from the Neologics investment?
What will Neologics use the US$1 million investment for?
When will Neologics complete registration and issue the equity certificate?
How does the transaction affect Neologics's capitalization?
